BioPharmSignal logoBioPharmSignal

Biotech News

Paratek Pharmaceuticals Completes Combination with Radius Health, Expanding Its Multi-Product Specialty Commercial Platform

Paratek Pharmaceuticals (PRTK)Paratek PharmaceuticalsCommercial

Transaction adds TYMLOS® to portfolio alongside NUZYRA® and XHANCE® and creates a diversified portfolio expected to generate nearly $1 billion in revenue in 2026

KING OF PRUSSIA, Pa., March 18, 2026 (GLOBE...

Related news

PRTKParatek Pharmaceuticals2025-03-19 21:25 EST

Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)

PRTKParatek Pharmaceuticals2023-10-05 08:00 EST

Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023

View all latest news

Paratek Pharmaceuticals

Paratek Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

PRTKParatek Pharmaceuticals2026-04-16 07:30 EST

Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2026

PRTKParatek Pharmaceuticals2026-03-18 07:00 EST

Paratek Pharmaceuticals Completes Combination with Radius Health, Expanding Its Multi-Product Specialty Commercial Platform

PRTKParatek Pharmaceuticals2026-02-24 07:30 EST

Paratek Pharmaceuticals Announces Positive Results for NUZYRA® Therapeutic Efficacy Studies in Inhalation Anthrax Triggering Additional Procurement under BARDA Project BioShield Contract

PRTKParatek Pharmaceuticals2025-10-17 07:30 EST

Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at IDWeek 2025 and CHEST 2025

PRTKParatek Pharmaceuticals2025-05-21 08:26 EST

Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States